Trellus Health plc

LSE TRLS.L

Trellus Health plc EBIT for the year ending December 31, 2023: USD -6.56 M

Trellus Health plc EBIT is USD -6.56 M for the year ending December 31, 2023, a 25.52% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Trellus Health plc EBIT for the year ending December 31, 2022 was USD -8.81 M, a -49.27% change year over year.
Trellus Health plc EBIT for the year ending December 31, 2021 was USD -5.90 M.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

LSE: TRLS.L

Trellus Health plc

CEO	Dr. Marla Cindy Dubinsky M.D.
IPO Date	May 31, 2021
Location	United States
Headquarters	44 South Broadway
Employees	31
Sector	Healthcare
Industries Telehealth Biotechnology Drugstores & Retail Pharmacies Pharmaceuticals Software-as-a-Service (SaaS)

Description

Trellus Health plc provides digital chronic condition management solutions for employers and health plans. The company offers TrellusElevate, a proprietary HIPAA-compliant technology platform to coordinate and deliver personalized care remotely through telemedicine. Its platform provides patients with access to a care team, educational content resources, and remote monitoring capabilities for the treatment of inflammatory bowel diseases, which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis. The company was founded in 2020 and is headquartered in White Plains, New York.

Key trends

Past 5 years